ALT5 Sigma (Nasdaq:ALTS) - 주가, 뉴스 및 분석

ALTS 주식 개요

ALT5 시그마는 차세대 블록체인 플랫폼을 운영하는 회사입니다. 자세한 내용

ALTS 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	0/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 80.1% 에서 거래

위험 분석

지난 1년 동안 주주가 크게 희석되었습니다.

의미 있는 시가총액이 없습니다. ( $31M )

최근 3개월간 주가 변동성

ALT5 Sigma Corporation 경쟁사

Lipocine

NasdaqCM:LPCN

US$27.5m

Cara Therapeutics

NasdaqCM:CARA

US$16.7m

Sol-Gel Technologies

NasdaqCM:SLGL

US$14.9m

IntelGenx Technologies

OTCPK:IGXT

US$29.2m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 ALT5 Sigma
과거 주가
현재 주가	US$2.19
52주 최고치	US$5.26
52주 최저치	US$0.36
베타	2.15
11개월 변경	-21.79%
3개월 변경 사항	-10.98%
1년 변경 사항	493.50%
33년 변화	-57.56%
5년 변화	-34.14%
IPO 이후 변화	-98.82%

최근 뉴스 및 업데이트

Does ALT5 Sigma (NASDAQ:ALTS) Have A Healthy Balance Sheet?

Nov 15

Recent updates

Does ALT5 Sigma (NASDAQ:ALTS) Have A Healthy Balance Sheet?

Nov 15

JanOne Inc.'s (NASDAQ:JAN) Share Price Boosted 153% But Its Business Prospects Need A Lift Too

Mar 31

JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry

Feb 14

Shareholders May Be A Bit More Conservative With JanOne Inc.'s (NASDAQ:JAN) CEO Compensation For Now

Oct 03

주주 수익률

	ALTS	US Pharmaceuticals	US 마켓
7D	-6.0%	1.6%	2.2%
1Y	493.5%	9.9%	31.6%

수익률 대 산업: ALTS 지난 1년 동안 9.9 %를 반환한 US Pharmaceuticals 산업을 초과했습니다.

수익률 대 시장: ALTS 지난 1년 동안 31.6 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is ALTS's price volatile compared to industry and market?
ALTS volatility
ALTS Average Weekly Movement	12.1%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

안정적인 주가: ALTS 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: ALTS 의 주간 변동성은 지난 1년 동안 20% 에서 12% 로 감소했지만 여전히 US 주식의 75%보다 높습니다.

회사 소개

설립	직원	CEO	웹사이트
1976	5	Peter Tassiopoulos	alt5sigma.com

ALT5 시그마 코퍼레이션은 차세대 블록체인 플랫폼을 운영합니다. 디지털 자산의 토큰화, 거래, 청산 결제, 결제 및 안전한 보관에 관여합니다. 이 회사의 제품에는 디지털 자산을 사고 팔 수 있는 전자 장외 거래 플랫폼인 ALT 5 Prime과 결제 프로세서가 디지털 자산을 결제 수단으로 받아들이고 디지털 자산으로 결제할 수 있도록 하는 ALT 5 Pay가 있습니다.

ALT5 Sigma Corporation 기본 사항 요약

ALT5 Sigma 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ALTS 기본 통계
시가총액	US$30.70m
수익(TTM)	-US$18.65m
수익(TTM)	US$7.11m

4.3x

P/S 비율

-1.6x

P/E 비율

ALTS 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ALTS 손익 계산서(TTM)
수익	US$7.11m
수익 비용	US$3.65m
총 이익	US$3.46m
기타 비용	US$22.11m
수익	-US$18.65m

최근 보고된 수익

Sep 28, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.33
총 마진	48.65%
순이익 마진	-262.26%
부채/자본 비율	46.4%

ALTS 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ALTS 주식 개요

보상

위험 분석

ALT5 Sigma Corporation 경쟁사

NasdaqCM:LPCN

US$27.5m

NasdaqCM:CARA

US$16.7m

NasdaqCM:SLGL

US$14.9m

OTCPK:IGXT

US$29.2m

가격 내역 및 성능

최근 뉴스 및 업데이트

Does ALT5 Sigma (NASDAQ:ALTS) Have A Healthy Balance Sheet?

New major risk - Revenue and earnings growth

High number of new directors

ALT5 Sigma Corporation Appoints Ron Pitters to Its Board of Directors

ALT5 Sigma Corporation, Annual General Meeting, Dec 18, 2024

ALT5 Sigma Corporation Announces Chief Executive Officer Changes

Recent updates

Does ALT5 Sigma (NASDAQ:ALTS) Have A Healthy Balance Sheet?

New major risk - Revenue and earnings growth

High number of new directors

ALT5 Sigma Corporation Appoints Ron Pitters to Its Board of Directors

ALT5 Sigma Corporation, Annual General Meeting, Dec 18, 2024

ALT5 Sigma Corporation Announces Chief Executive Officer Changes

ALT5 Sigma Corporation announced delayed 10-Q filing

Insufficient new directors

JanOne Regains Compliance with Nasdaq's Listing Rule 5550(b)(1)

JanOne Inc. (NasdaqCM:JAN) completed the acquisition of Alt 5 Sigma Inc.

JanOne Inc.'s (NASDAQ:JAN) Share Price Boosted 153% But Its Business Prospects Need A Lift Too

JanOne Inc. announced delayed annual 10-K filing

JanOne Regains Compliance with Nasdaq’s Listing Requirements

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 93%

JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry

New minor risk - Profit margin trend

New major risk - Shareholder dilution

New major risk - Share price stability

Shareholders May Be A Bit More Conservative With JanOne Inc.'s (NASDAQ:JAN) CEO Compensation For Now

JanOne Receives Non-Compliance Notice from the Nasdaq Stock Market

JanOne Inc., Annual General Meeting, Oct 09, 2023

New minor risk - Share price stability

New major risk - Earnings quality

Janone Inc. Files International Patent Application for Methods of Using Low Dose Naltrexone to Treat Chronic Pain

JanOne Inc. announced delayed 10-Q filing

Full year 2022 earnings released: EPS: US$1.14 (vs US$6.35 loss in FY 2021)

JanOne Received A Notice from the NASDAQ Stock Market

Third quarter 2022 earnings released: US$0.66 loss per share (vs US$0.34 loss in 3Q 2021)

High number of new and inexperienced directors

JanOne Inc., Annual General Meeting, Nov 02, 2022

JanOne Inc. (NasdaqCM:JAN) enter into a term sheet to acquire Soin Therapeutics LLC Soin Therapeutics LLC for $30 million.

JanOne to acquire Soin Therapeutics

Does JanOne (NASDAQ:JAN) Have A Healthy Balance Sheet?

Second quarter 2022 earnings released: EPS: US$3.39 (vs US$2.07 loss in 2Q 2021)

JanOne Inc. Announces an Improved Formulation of JAN101

JanOne Inc. Announces the Issuance of U.S. Patent Covering A Method of Improving Nerve Function Using Jan101

First quarter 2022 earnings released: EPS: US$0.43 (vs US$0.26 in 1Q 2021)

High number of new and inexperienced directors

JanOne Receives Notice from Nasdaq for Not Complying with Listing Rules

Full year 2021 earnings released: US$6.35 loss per share (vs US$4.59 loss in FY 2020)

Health Check: How Prudently Does JanOne (NASDAQ:JAN) Use Debt?

Is JanOne (NASDAQ:JAN) Using Debt In A Risky Way?

Third quarter 2021 earnings released: US$0.34 loss per share (vs US$0.43 loss in 3Q 2020)

High number of new and inexperienced directors

Janone Janone Inc. Revises Its Development Strategy Regarding Phase 2B Clinical Trial Design of Lead Drug Candidate Jan101

Janone Inc. Readies Clinical Supply of Lead Product Candidate Jan101 for Distribution to Phase 2B Trial Sites

JanOne Selects Regulatory Partner for Phase 2B Trial as Investigational Plan Is Prepared for FDA Filing

JanOne adds Nicholas Goeders to scientific advisory board

JanOne Announces Initiation of Phase 2b Peripheral Artery Disease Trial for Lead Product Candidate JAN101

JanOne advances toward initiation of mid-stage peripheral artery disease trial

Chief Financial Officer recently sold US$221k worth of stock

First quarter 2021 earnings released: EPS US$0.26 (vs US$1.33 loss in 1Q 2020)

Full year 2020 earnings released: US$4.59 loss per share (vs US$6.78 loss in FY 2019)

Virland Johnson entered into a definitive agreement to acquire substantially all assets and certain liabilities of ARCA Recycling, Inc. from JanOne Inc. (NasdaqCM:JAN) for $25 million.

JanOne Inc. has completed a Follow-on Equity Offering in the amount of $5.999994 million.

JanOne under pressure on pricing $6M stock offering

New 90-day high: US$5.47

New 90-day high: US$5.08